Celanese Corp. 2024 Q2 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Celanese Corporation is a global chemical and specialty materials company operating primarily through two segments: Engineered Materials (high-performance polymers) and Acetyl Chain (intermediate chemicals). The company is currently focused on deleveraging following the 2022 acquisition of the Mobility & Materials business from DuPont.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales ($ millions) | 2,651 | 2,795 | 5,262 | 5,648 |
| Operating Profit ($ millions) | 250 | 335 | 460 | 586 |
| Net Earnings Attributable to Celanese ($ millions) | 155 | 220 | 276 | 311 |
| Diluted EPS ($) | 1.41 | 2.01 | 2.52 | 2.85 |
| Operating Margin (%) | 9.4% | 12.0% | 8.7% | 10.4% |
| Free Cash Flow Proxy (Operating Cash Flow) ($ millions) | N/A | N/A | 393 | 666 |
| Total Debt ($ millions) | 13,035 | N/A | 13,035 | 13,684 |
| Cash and Cash Equivalents ($ millions) | 1,185 | N/A | 1,185 | 1,805 |
Note: YTD Operating Cash Flow decreased $273 million to $393 million, driven by higher cash taxes paid and unfavorable working capital changes.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5% in Q2 and 7% YTD compared to 2023. This was driven by lower pricing (due to balanced supply/demand and competitive markets), lower volumes in Engineered Materials (partially due to the Nutrinova joint venture formation), and unfavorable currency impacts (weaker CNY and JPY).
- Profitability Pressure: Operating profit declined 25% in Q2 and 22% YTD. Key headwinds included restructuring costs of $43 million in Q2 (totaling $57 million YTD) related to facility closures in Mechelen, Belgium, and Uentrop, Germany, as well as $56 million in accelerated depreciation YTD.
- Segment Performance:
- Engineered Materials: Sales down 7% (Q2) and 12% (YTD); Operating profit down 13% (Q2) and 16% (YTD).
- Acetyl Chain: Sales down 3% (Q2) and 1% (YTD); Operating profit down 18% (Q2) and 13% (YTD).
- Debt Reduction: Total debt decreased to $13.0 billion from $13.7 billion at year-end 2023. Subsequent to the quarter end, the company repaid $1.47 billion in senior notes due July 2024.
Guidance, Outlook, and Risks
- Capital Allocation: The company has paused its share repurchase program to prioritize deleveraging. It expects total capital expenditures to be approximately $425 million in 2024, focusing on maintenance and productivity improvements.
- Restructuring Outlook: The company expects to incur an additional $68 million in exit/shutdown costs for the Mechelen facility through 2028 and $11 million for the Uentrop facility through 2027.
- Liquidity: Management believes liquidity from operations and available credit facilities ($1.75 billion U.S. revolver, $62 million China revolver) is sufficient to meet obligations for the next 12 months.
- Risks: Key risks include geopolitical instability, raw material price volatility, the ability to pass on cost increases, and ongoing tax audits in the U.S., Netherlands, Germany, Mexico, and Canada. The company is also subject to capital controls in China.
Investor Verification Checklist
- Restructuring Costs: Verify the timeline and total expected cost for the Mechelen and Uentrop closures against future cash flow projections.
- Debt Maturity Wall: Confirm the successful repayment of the $1.47 billion note due July 2024 and the impact on the leverage ratio.
- Working Capital Trends: Monitor inventory levels and trade receivables, as unfavorable working capital significantly impacted YTD operating cash flow.
- Segment Margins: Assess whether the Acetyl Chain segment can recover margins given the "balanced global demand and supply environment" cited by management.
- Tax Audits: Review the status of ongoing audits in Germany and the U.S., as resolution could materially impact future tax provisions.